Sinorda Pharmaceutical Wins Three Awards in the "Top 50 Biotech Innovators of the Greater Bay Area" at the 7th Edition
Sinorda Pharmaceutical has been honored with the titles of "2024 Investment-Value Enterprise" and "Pioneer Enterprise," while Dr. Hu Pingsheng, Chairman of the company, was awarded the prestigious "2024 Scientist of the Year" prize. IMG_258 IMG_257 IMG_256 Since its establishment in 2010, Sinorda Pharma has remained steadfastly focused on developing innovative drugs in the fields of gastrointestinal diseases and tumor immunotherapy. Leveraging its comprehensive biopharmaceutical R&D capabilities, the company continues to drive technological innovation and breakthroughs. Currently, the company’s globally innovative drug, linagliptin succinate, has successfully obtained the *Drug Registration Certificate* (National Drug Approval Number H20240042), and Sinorda is actively pursuing licensing agreements in several Asian countries. In addition, other pipeline products currently in clinical stages also demonstrate remarkable innovation and originality, addressing unmet medical needs and promising to bring significant benefits to more patients. This year’s selection process involved rigorous screening from over 1,000 companies, ultimately identifying 50 enterprises recognized for their exceptional potential and strength. The organizers evaluated each company comprehensively and thoroughly, considering multiple dimensions such as innovative technologies, market applications, and capital investment—alongside factors like core product development, service quality enhancement, R&D team building, technology patent acquisition, and corporate financial management. This multi-faceted assessment aims to uncover future unicorns in the biotech sector and propel the industry toward deeper, more sustainable growth. Against this backdrop, Sinorda Pharma has earned recognition in this prestigious selection due to its deep-rooted commitment to biotechnology and relentless pursuit of innovation. This achievement not only acknowledges the company’s past efforts but also underscores the high expectations placed on Sinorda Pharma to continue leading industry advancements and shaping emerging trends. Moving forward, Sinorda Pharma will remain dedicated to a pragmatic and innovative growth strategy, ramping up R&D investments, deepening technological breakthroughs, and striving to make even greater contributions to human health and well-being.
On December 26, 2024, the award ceremony for the 7th Guangdong-Hong Kong-Macao Greater Bay Area Biotech Innovation Top 50 was held in Guangzhou, where Sinorda Pharma was honored with two prestigious awards: "Investment-Value Enterprise of the Year 2024" and "Pioneering Enterprise." Dr. Hu Pingsheng, Chairman of the company, also received the distinguished "Scientist of the Year 2024" award.
Since its establishment in 2010, Sinorda Pharma has consistently focused on the research and development of innovative drugs in the fields of gastrointestinal diseases and tumor immunotherapy. Leveraging its comprehensive biopharmaceutical R&D capabilities, the company continues to drive technological innovation and breakthroughs. Currently, the company’s globally innovative drug, linagliptin succinate, has successfully obtained the Drug Registration Certificate (National Drug Approval Number H20240042) and is actively advancing licensing efforts in Asian countries. In addition, other products developed by the company that are currently in clinical stages also demonstrate remarkable innovation and originality, addressing unmet market needs and poised to bring significant benefits to more patients.
This selection process involved rigorous, multi-stage screening from over 1,000 companies, ultimately identifying 50 enterprises that demonstrate the greatest potential and strength. The organizers evaluated these companies comprehensively and in depth, considering factors such as innovative technologies, market applications, and capital resources—while also assessing their core product development, enhancements in service quality, advancements in R&D team building, acquisition of technology patents, and robust corporate financial management. The goal is to uncover future unicorns in the biotech sector and drive the industry’s sustained, in-depth growth.
Against this backdrop, Sinorda Pharma has been honored with the award in this selection, thanks to its deep-rooted expertise and continuous innovation in the biotechnology field. This recognition not only acknowledges Sinorda Pharma's past efforts but also underscores the company's promising contributions to driving industry progress and shaping future trends. Moving forward, Sinorda Pharma will remain committed to a pragmatic and innovative growth strategy, ramping up R&D investments, deepening technological advancements, and striving to make even greater strides in advancing human health.
Related content
2026-01-29 08:54
Consultation Hotline
